ACET
Adicet Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
RSI Oversold
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACET
Adicet Bio, Inc.
A company that developing novel therapeutics for the treatment of aging-related diseases
131 Dartmouth Street, 3rd Floor, Boston, MA 02116
--
Adicet Bio, Inc., was incorporated under the laws of the State of Delaware on July 5, 2016. The company is a clinical-stage biotechnology company that discovers and develops allogeneic gamma delta T cell therapies for cancer. They are advancing a series of "off-the-shelf" gamma delta T cells designed with chimeric antigen receptors (CAR) and T cell receptor like antibodies (TCRL) to enhance tumor selective targeting, promote innate and adaptive anti-tumor immune response, and improve the persistence of long-lasting activity in patients. Their method of activating, designing and manufacturing allogeneic gamma delta T cell product candidates from peripheral blood cells of unrelated donors enables them to generate new product candidates in a rapid and cost-effective manner.
Company Financials
EPS
ACET has released its 2025 Q3 earnings. EPS was reported at -0.29, versus the expected -0.32, beating expectations. The chart below visualizes how ACET has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
